Catalyst Wire Dossier Catalyst Wire Dossier

CD19- and CD22-targeted CAR-T therapy

· Kecellitics Biotech Company Ltd
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CD19- and CD22-targeted CAR-T therapy, covering 2022-12-14 to 2023-04-18. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma [Phase 1, Phase 2]

See pricing